GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PhotoCure ASA (OTCPK:PHCUF) » Definitions » EPS without NRI

PhotoCure ASA (PhotoCure ASA) EPS without NRI : $0.02 (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is PhotoCure ASA EPS without NRI?

PhotoCure ASA's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.03. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for PhotoCure ASA's EPS without NRI or its related term are showing as below:

During the past 13 years, PhotoCure ASA's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 28.30% per year. The lowest was -22.30% per year. And the median was 12.80% per year.

PHCUF's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.2
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

PhotoCure ASA's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.02.

PhotoCure ASA's EPS (Basic) for the three months ended in Mar. 2024 was $-0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.02.


PhotoCure ASA EPS without NRI Historical Data

The historical data trend for PhotoCure ASA's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhotoCure ASA EPS without NRI Chart

PhotoCure ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 -0.07 -0.07 -0.27 0.01

PhotoCure ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 0.02 -0.02 0.05 -0.03

Competitive Comparison of PhotoCure ASA's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhotoCure ASA's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where PhotoCure ASA's PE Ratio without NRI falls into.



PhotoCure ASA EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PhotoCure ASA  (OTCPK:PHCUF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


PhotoCure ASA EPS without NRI Related Terms

Thank you for viewing the detailed overview of PhotoCure ASA's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


PhotoCure ASA (PhotoCure ASA) Business Description

Traded in Other Exchanges
Address
Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products specialty pharmaceutical companies. Its technology platform is focused on the field of photodynamic diagnosis and treatment of cancer. It has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, Netherlands, Other European countries, and the United States.